The Silent Threat of Measles: A Decade-Old Virus, A Lifetime of Risk
The story of Deepanwita Dasgupta, an 8-year-old girl from Bangalore, India, now paralyzed and unable to speak, is a stark warning. Her initial symptoms – stumbling and bruises – were easily dismissed as childhood mishaps. But these were the first signs of subacute sclerosing panencephalitis (SSPE), a rare but devastating neurological condition triggered by a measles infection she likely contracted as an infant. Her case, and others emerging globally, highlight a chilling reality: measles isn’t just a childhood illness; it’s a potential ticking time bomb.
A Delayed Reaction: How Measles Can Strike Years Later
Measles, while often perceived as a disease of the past, is making a concerning comeback. And with that resurgence comes the risk of SSPE. The virus can remain dormant in the nervous system for years, even decades, before triggering debilitating neurological damage. “People think, ‘Oh, you know, if we get measles, then we’ll be fine, because I know my neighbor had it and they’re fine,’” explains Yasmin Khakoo, who leads the national Child Neurology Society. This perception is dangerously misleading.
The risk of developing SSPE is estimated to be about 1 in 10,000 people who get measles, but that risk is significantly higher for those infected before age 5. Researchers now estimate that 1 case is diagnosed for about every 600 infected babies. The insidious nature of SSPE means that even individuals who seemingly recover fully from measles can be vulnerable.
Rising Cases and a Renewed Warning
Since the start of 2025, the Centers for Disease Control and Prevention has recorded over 3,500 measles cases – more than in the entire preceding decade. This surge, largely driven by declining vaccination rates, is fueling fears of a corresponding increase in SSPE cases. Recent diagnoses in the U.S., including a 6-year-old in Connecticut and a school-age child in California who died after contracting measles as an infant, are sounding the alarm.
Doctors are now actively working to raise awareness about SSPE, even publishing educational videos for clinicians. “We don’t have a way of knowing who’s going to get it, and we don’t have a way of very effectively treating it,” says Aaron Nelson, a professor of neurology with the New York University Grossman School of Medicine. “The one best thing that we can do, ideally, is to prevent children from having to go through it in the first place.”
Global Impact: India and Beyond
The impact of measles and subsequent SSPE is particularly acute in populous nations like India, where the virus remains endemic. Approximately 200 families caring for individuals with SSPE are connected in a support group in the Bangalore area alone. Sheffali Gulati, who studies SSPE in New Delhi, sees about 10 new patients each year, with diagnoses occurring in children as young as 3 years old.
Globally, outbreaks are increasing in places like the U.K. And Italy, prompting concerns about a wider resurgence of SSPE. Researchers are working to understand the mechanisms behind the delayed onset of the disease, but the most effective solution remains readily available: vaccination.
The Power of Prevention: Vaccination as a Shield
The measles vaccine is highly effective, reducing the risk of infection from 90% to 3%. This translates directly to a reduced chance of developing SSPE. While vaccines carry minimal risks, such as febrile seizure and a bleeding condition, these are far outweighed by the dangers of contracting measles itself.
Herd immunity – where at least 95% of the population is immune – is crucial to protect vulnerable individuals who cannot be vaccinated, such as infants and those with compromised immune systems. The recent decline in vaccination rates is eroding this protection, leaving communities increasingly susceptible to outbreaks and the long-term consequences of measles.
Research and the Future of SSPE
Roberto Cattaneo, a molecular biologist at the Mayo Clinic, is studying how the measles virus spreads within the brain, hoping to unlock potential treatments. However, he emphasizes that the most effective approach is prevention. “The problem could be solved with vaccination,” Cattaneo states. “It’s just painful.”
Frequently Asked Questions
- What is SSPE? SSPE, or subacute sclerosing panencephalitis, is a rare but fatal neurological condition that can develop years after a measles infection.
- How common is SSPE? Approximately 1 in 10,000 people who get measles will develop SSPE.
- Can SSPE be treated? Currently, there is no cure for SSPE, and treatments are limited to slowing the progression of the disease.
- How can I protect my child from SSPE? The most effective way to protect your child is to ensure they receive two doses of the measles vaccine.
Pro Tip: Stay informed about measles outbreaks in your area and consult with your healthcare provider about vaccination schedules.
The stories of children like Deepanwita Dasgupta serve as a powerful reminder: measles is not a benign illness. It’s a preventable disease with potentially devastating long-term consequences. Protecting our communities through vaccination is not just a personal choice; it’s a collective responsibility.
Did you know? Measles can remain contagious for four days before symptoms even appear, making it incredibly easy to spread.
Share your thoughts on the importance of vaccination in the comments below. Explore our other articles on public health and disease prevention to learn more.
Related reading